START will leverage Trialing’s platform to distribute curated information on ongoing early-phase oncology trials.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In this global phase III ...

The Health Management Academy's executive forum recognized alongside ASCO, AACR, and other leading gatherings in ...

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this ...

"This is changing the way we practice prostate cancer." ...

SynOx Therapeutics completed enrollment for the phase 3 TANGENT study of emactuzumab for tenosynovial giant cell tumors, with results expected in 2026. ALX Oncology launched a phase 1 trial of ALX2004 ...

A narrative review examines how generative AI tools such as large language models and vision-language models could assist precision oncology by interpreting genomic data, matching patients to clinical ...

Jody Agena, PharmD, MBA, director of pharmacy operations, Virginia Cancer Specialists, discusses the various responsibilities of the pharmacist within community oncology settings. The clinical ...

Dr. Rasha Kelej Continues to Advance Cancer Care in Africa by Providing 269 Oncology Scholarships for 34 African Countries and Beyond ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...